Skip to content

Opus Genetics IRD Common Stock Shares Issued

Common Stock Shares Issued at other companies

Prime Medicine logo
Prime MedicinePRME
180.6M+37.7%
Precigen logo
PrecigenPGEN
355.9M+20.6%
HRO
HarrowHROW
37.3M+4.5%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's common stock shares issued?
Opus Genetics (IRD) reported common stock shares issued of 71.4M in Q1 2026.
How has Opus Genetics's common stock shares issued changed year-over-year?
Opus Genetics's common stock shares issued increased by 57.0% year-over-year, from 45.5M to 71.4M.
What is the long-term trend for Opus Genetics's common stock shares issued?
Over 5 years (2020 to 2025), Opus Genetics's common stock shares issued has grown at a 45.1% compound annual growth rate (CAGR), from 10.9M to 69.9M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.